The estimated Net Worth of Robert S. White is at least $2.67 Million dollars as of 23 February 2024. Mr. White owns over 10,000 units of Atricure Inc stock worth over $2,393,697 and over the last 12 years he sold ATRC stock worth over $83,339. In addition, he makes $197,478 as Independent Director at Atricure Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Mr. White ATRC stock SEC Form 4 insiders trading
Robert has made over 6 trades of the Atricure Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 10,000 units of ATRC stock worth $159,600 on 23 February 2024.
The largest trade he's ever made was exercising 20,000 units of Atricure Inc stock on 27 February 2023 worth over $169,600. On average, Robert trades about 3,499 units every 118 days since 2013. As of 23 February 2024 he still owns at least 88,985 units of Atricure Inc stock.
You can see the complete history of Mr. White stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Robert White biography
Robert J. White serves as Independent Director of the Company. Mr. White has served as one of our directors since March 2013. Mr. White is an operating partner of EW Healthcare Partners since May 2018. Most recently, Mr. White served as President and Chief Executive Officer of Entellus Medical, Inc., which was acquired by Stryker Corporation in February 2018, a publicly-traded company that delivered innovative, high quality, minimally-invasive therapeutic solutions to healthcare providers and their patients who suffer from sinusitis. Prior to joining Entellus, Mr. White served as President and CEO of TYRX, a privately-held company acquired by Medtronic, Inc. TYRX commercialized innovative, implantable combination drug and device products focused on infection control. Prior to joining TYRX, Mr. White held several senior leadership positions with Medtronic, Inc. Mr. White served as President of Medtronic Kyphon following its $3.9 billion acquisition of the spinal treatment business. During his time with Medtronic, Mr. White also served as President of Physio Control and was responsible for commercial operations of the Cardiac Rhythm Disease Management business as Vice President of U.S. Sales and Global Marketing. Earlier in his career, Mr. White held positions with General Electric Company and Eli Lilly and Company, among others. Mr. White recently served on the Board of Directors of HyperBranch Medical Technology, a privately-held company that develops and markets products capable of adhering tissues, promoting healing, preventing fluid and air leaks, and reducing infections, until it was acquired by Stryker Corporation in October 2018. Mr. White also served on the Board of Directors of Novadaq, a publicly-traded provider of clinically relevant imaging solutions for use in surgical and diagnostic procedures, until it was acquired by Stryker Corporation in June 2018. Mr. White holds a B.S. in Aerospace Engineering from the University of Missouri-Rolla and an M.B.A. from Cornell University.
What is the salary of Robert White?
As the Independent Director of Atricure Inc, the total compensation of Robert White at Atricure Inc is $197,478. There are 8 executives at Atricure Inc getting paid more, with Michael Carrel having the highest compensation of $5,829,780.
How old is Robert White?
Robert White is 58, he's been the Independent Director of Atricure Inc since 2013. There are 5 older and 7 younger executives at Atricure Inc. The oldest executive at Atricure Inc is Sven Wehrwein, 69, who is the Independent Director.
What's Robert White's mailing address?
Robert's mailing address filed with the SEC is 3600 Holly Ln N #40, Plymouth, MN 55447, USA.
Insiders trading at Atricure Inc
Over the last 19 years, insiders at Atricure Inc have traded over $52,789,242 worth of Atricure Inc stock and bought 666,621 units worth $5,937,195 . The most active insiders traders include Scott William Drake, Group I, Llc Donoghue Danie..., and Management Group Viii L L C.... On average, Atricure Inc executives and independent directors trade stock every 24 days with the average trade being worth of $548,410. The most recent stock trade was executed by Maggie Yuen on 15 August 2024, trading 3,500 units of ATRC stock currently worth $84,245.
What does Atricure Inc do?
atricure, inc. provides innovative technologies for the treatment of afib and related conditions. afib affects more than 33 million people worldwide. electrophysiologists and cardiothoracic surgeons around the globe use atricure technologies for the treatment of afib and reduction of afib related complications. atricure’s isolator® synergy™ ablation system is the first and only medical device to receive fda approval for the treatment of persistent afib. atricure’s atriclip left atrial appendage exclusion system products are the most widely sold laa management devices worldwide, with more than 100,000 implanted to date. for more information, visit atricure.com or follow us on twitter @atricure.
What does Atricure Inc's logo look like?
Complete history of Mr. White stock trades at Atricure Inc
Atricure Inc executives and stock owners
Atricure Inc executives and other stock owners filed with the SEC include:
-
Michael Carrel,
President, Chief Executive Officer, Director -
Douglas Seith,
Chief Operating Officer -
Salvatore Privitera,
Chief Technology Officer -
Justin Noznesky,
Senior Vice President, Marketing and Business Development -
Scott Drake,
Independent Chairman of the Board -
Sven Wehrwein,
Independent Director -
Mark Lanning,
Independent Director -
B. Kristine Johnson,
Independent Director -
Robert White,
Independent Director -
Regina Groves,
Independent Director -
Mark Collar,
Independent Director -
Karen Prange,
Independent Director -
Daniel Florin,
Independent Director -
Angela Wirick,
Chief Financial Officer -
Shlomo Nachman,
Director -
Karen P Robards,
Director -
Elizabeth D Krell,
Director -
Richard M Johnston,
Director -
Michael D Hooven,
Director -
Andrew L Lux,
V.P. & Chief Operating Officer -
Group I, Llc Murphy Michael...,
-
M. Andrew Wade,
CFO -
Tonya Austin,
Chief Human Resources Officer -
Deborah L Morley,
VP Clinical Affairs -
Lee R Wrubel,
Director -
Maureen Shaffer,
Vice President Marketing -
Jon A Sherman,
VP Product Development -
Elsa Chi Abruzzo,
VP; Regulatory&ClinicalAffairs -
Alan L Kaganov,
Director -
Richard S Walsh,
Vice President; Sales -
Management Group Viii L L C...,
-
Management Group Viii L L C...,
-
Stephen S Cambridge,
Vice President; Sales -
Management Group Viii L L C...,
-
Thomas J Etergino,
Vice President and CFO -
Norman R Weldon,
Director -
Patricia J Kennedy,
VP, GM, International -
James L Lucky,
VP; QA & Healthcare Compliance -
Management Group Viii L L C...,
-
David J Drachman,
President and CEO -
Richard Mcamden Partners St...,
-
Richard Mcamden Partners St...,
-
Donald C Harrison,
Director -
Group I, Llc Donoghue Danie...,
-
Stewart W Strong,
Vice President US Sales -
Management Group Viii L L C...,
-
Frederick Preiss,
Vice President; Operations -
Julie A Piton,
VP and CFO -
Deborah H Telman,
Director -
Karl S. Dahlquist,
Chief Legal Officer -
Vinayak Doraiswamy,
Chief Scientific Officer -
Maggie Yuen,
Director -
Deborah Lee Yount,
Chief Human Resources Officer